摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-氯-4-乙氧基二氮杂萘 | 22378-29-6

中文名称
1-氯-4-乙氧基二氮杂萘
中文别名
——
英文名称
1-chloro-4-ethoxyphthalazine
英文别名
——
1-氯-4-乙氧基二氮杂萘化学式
CAS
22378-29-6
化学式
C10H9ClN2O
mdl
MFCD10698632
分子量
208.647
InChiKey
KQLFVZGMRLYYBY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    78 °C
  • 沸点:
    402.8±25.0 °C(Predicted)
  • 密度:
    1.284±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    35
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933990090

SDS

SDS:e38a30e5ad38a7b2560080941c6882cf
查看

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    DE847748
    摘要:
    公开号:
  • 作为产物:
    描述:
    参考文献:
    名称:
    Hepatitis C Virus Inhibitors
    摘要:
    丙型肝炎病毒抑制剂具有通式(I)如下。还公开了包含这些化合物的组合物以及使用这些化合物抑制HCV的方法。
    公开号:
    US20130115190A1
  • 作为试剂:
    描述:
    1,4-二氯酞嗪乙醇 在 crude product 、 silica gel 、 乙酸乙酯正己烷1-氯-4-乙氧基二氮杂萘 作用下, 反应 0.5h, 以to give 200 mg of the crude product 1-chloro-4-ethoxyphthalazine的产率得到1-氯-4-乙氧基二氮杂萘
    参考文献:
    名称:
    Hepatitis C virus inhibitors
    摘要:
    公开了具有一般式(I)的丙型肝炎病毒抑制剂。还公开了包含该化合物的组合物以及使用该化合物抑制HCV的方法。
    公开号:
    US08957203B2
点击查看最新优质反应信息

文献信息

  • Allylthiopyridazine derivatives and process for preparing the same
    申请人:Kwon; Soon Kyoung
    公开号:US05942511A1
    公开(公告)日:1999-08-24
    The, present invention relates to a novel allylthiopyridazine derivative represented by formula (I) which exhibits a superior effect for prevention and treatment or hepatic diseases induced by toxic substances and for protection of human tissues from radiation: ##STR1## or a pharmaceutically acceptable salt thereof, in which R.sub.1 represents halogen atom, lower alkoxy, dialkylaminoalkoxy, hydroxyalkoxy, phenoxy substituted or unsubstituted with lower alkyl, benzyloxy, or phenyl, and R.sub.2 and R.sub.3 independently of one another represent hydrogen or lower alkyl, or R.sub.2 and R.sub.3 together with carbon atom to which they are attached can form a saturated or unsaturated 6-membered ring, provided that R.sub.2 and R.sub.3 are other than hydrogen when R.sub.1 is chloro; and to a process for preparing thereof and a pharmaceutical composition containing the same as an effective component.
    本发明涉及一种新型的烯丙基噻吡嗪衍生物,其化学式表示为(I),该化合物对预防和治疗由有毒物质诱导的肝脏疾病以及保护人体组织免受辐射的作用优越:##STR1##或其药用盐,其中R.sub.1代表卤原子,较低的烷氧基,二烷基氨氧基烷基,羟基烷氧基,苯氧基,取代或未取代较低烷基,苄氧基或苯基的苯氧基,而R.sub.2和R.sub.3彼此独立地表示氢或较低烷基,或R.sub.2和R.sub.3与它们连接的碳原子一起可以形成饱和或不饱和的6元环,前提是当R.sub.1为氯时,R.sub.2和R.sub.3不是氢;以及制备该化合物的方法和含有其作为有效成分的药物组合物。
  • HEPATITIS C VIRUS INHIBITORS
    申请人:BRISTOL-MYERS SQUIBB COMPANY
    公开号:US20150284391A1
    公开(公告)日:2015-10-08
    Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    公开了具有一般式(I)的丙型肝炎病毒抑制剂。还公开了包含该化合物的组合物以及使用该化合物抑制丙型肝炎病毒的方法。
  • 1,4-hydrazino-phthalazine and its acid salts
    申请人:CIBA PHARM PROD INC
    公开号:US02484785A1
    公开(公告)日:1949-10-11
  • NOVEL ALLYLTHIOPYRIDAZINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME
    申请人:Seoul Pharm. Co., Ltd.
    公开号:EP1058681B1
    公开(公告)日:2003-05-07
  • ——
    作者:V. V. Yanilkin、B. I. Buzykin、V. I. Morozov、N. V. Nastapova、N. I. Maksimyuk、R. M. Eliseenkova
    DOI:10.1023/a:1013979709884
    日期:——
    Electrochemical reduction in dimethylformamide of unsymmetrical 1-Cl-4-X-phthalazines and symmetrical 1,4-X-2-phthalazines (X = Cl, PhO, MeO, EtO, i-PrO) was studied by voltammetry and electrolysis-ESR. The electron trasfer on 1,4-dichlorophthalazine and unsymmetrical 1-Cl-4-X-phthalazines induces anionoid elimination of Cl and X, pyridazine ring cleavage, and phthalonitrile formation. In this previously unknown process the transfer of two electrons induces cleavage of three sigma bonds and formation of two new pi bonds. The reduction of 1,4-dialkoxy(diaryloxy)phthalazines involves formation of stable radical anions which undergo no heteroring cleavage. Possible mechanisms of the processes studied were discussed. It was assumed that the same mechanism with pyridazine ring cleavage may be realized with other phthalazine derivatives and heteroannelated pyridazines containing readily leaving nucleofuge groups alpha to nitrogens.
查看更多